Nykode Therapeutics
Clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies.
Launch date
Employees
Market cap
$219m
Enterprise valuation
$48m (Public information from Sep 2024)
Share price
NOK5.1 NYKD.OL
Company register number 990646066
Oslo Norway (HQ)
Financials
Estimates*
| NOK | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.8b | 281m | 59.2m | 107m | 104m | 249m | 107m |
| % growth | 3204304 % | (84 %) | (79 %) | 80 % | (2 %) | 139 % | (57 %) |
| EBITDA | 1.5b | (85.7m) | (405m) | (345m) | (609m) | (613m) | (1.0b) |
| % EBITDA margin | 84 % | (31 %) | (684 %) | (324 %) | (584 %) | (246 %) | (976 %) |
| Profit | 1.2b | (77.8m) | (353m) | (290m) | (540m) | (678m) | (942m) |
| % profit margin | 70 % | (28 %) | (596 %) | (272 %) | (517 %) | (273 %) | (880 %) |
| EV / revenue | 12.0x | 76.6x | 104.1x | 50.0x | 7.9x | 6.5x | 25.4x |
| EV / EBITDA | 14.3x | -250.8x | -15.2x | -15.4x | -1.4x | -2.6x | -2.6x |
| R&D budget | 87.8m | 135m | 221m | 243m | - | - | - |
| R&D % of revenue | 5 % | 48 % | 374 % | 228 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Grant | ||
$2.6m | Grant | ||
* | NOK2.5m | Seed | |
$6.9m | Late VC | ||
$25.0m Valuation: $44.9m | Late VC | ||
NOK4.0m | Grant | ||
| N/A | N/A | IPO | |
* | N/A | $45.0m | Private Placement VC |
| Total Funding | $80.3m | ||
Related Content
Recent News about Nykode Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.